Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus

Table 1 Baseline demographic data and clinical characteristics of chronic hepatitis B patients, n (%)/mean ± SD/95%CI

Variable	Chronic hepatitis B	Complete virologic response	Partial virologic response	t/χ2	P value
	(n = 465)	(n = 139)	(n = 326)
Gender (n = 465)				χ2 = 0.006	0.940
Male	320 (68.8)	96 (69.1)	224 (68.7)
Female	145 (31.2)	43 (30.9)	102 (31.3)
Age (years), n = 465	35.5 ± 10.5	38.1 ± 11.7	34.4 ± 9.7	t = 3.514	0.0005
HBV DNA baseline level, log10 (IU/mL), n = 465	6.1 ± 6.0	5.6 ± 1.9	6.4± 2.0	t = 3.661	0.0003
Virus shedding time (months), n = 428	9.8 ± 8.7	6.9 ± 5.8	11.2 ± 9.5	t = 4.919	< 0.0001
HBsAg baseline level, log10 (IU/mL + 1), n = 461	3.4 ± 1.0	3.0 ± 0.9	3.6 ± 1.0	t = 5.479	< 0.0001
HBeAg				χ2 = 14.57	< 0.0001
Positive	298 (64.1)	71 (51.1)	227 (69.6)
Negative	167 (35.9)	68 (48.9)	99 (30.4)
NAFLD				χ2 = 5.815	0.016
Yes	133 (28.6)	29 (20.9)	104 (31.9)
No	332 (71.4)	110 (79.1)	222 (68.1)
Leucocytes (G/L), n = 396	5.5 ± 1.7	5.4 ± 1.8	5.6 ± 1.6	t = 0.7417	0.4587
Haemoglobin (g/L), n = 396	148.2 ± 18.2	148.6 ± 17.2	147.9 ± 18.7	t = 0.3339	0.7386
Neutrophils (G/L), n = 396	3.2 ± 1.4	3.2 ± 1.4	3.3 ± 1.4	t = 0.6343	0.5263
Lymphocytes (G/L), n = 396	1.8 ± 0.6	1.8 ± 0.6	1.8 ± 0.6	t = 0.0444	0.9646
Total bilirubin log10 (μmol/L), n = 464	1.2 ± 0.2	1.2 ± 0.2	1.2 ± 0.2	t = 0.8594	0.3906
Alanine aminotransferase log10 (U/L), n = 464	1.7 ± 0.4	1.7 ± 0.4	1.7 ± 0.4	t = 0.6270	0.5310
Aspartate aminotransferase log10 (U/L), n = 464	1.6 ± 0.3	1.6 ± 0.3	1.6 ± 0.3	t = 1.432	0.1527
Albumin (g/L), n = 464	44.9 ± 3.3	44.9 ± 3.5	44.9 ± 3.2	t = 0.0135	0.9892
Uric acid (umol/L), n = 447	337.5 ± 92.8	327.7 ± 76.5	341.6 ± 98.8	t = 1.454	0.1467
Fasting glucose (mmol/L), n = 229	5.5 ± 1.1	5.6 ± 1.5	5.4 ± 0.9	t = 1.283	0.2009
Triglyceride (mmol/L), n = 264	1.4 ± 1.1	1.2 ± 0.6	1.4 ± 1.2	t = 2.056	0.0408
Total cholesterol (mmol/L), n = 264	4.5 ± 1.0	4.4 ± 1.0	4.9 ± 0.9	t = 3.694	0.0003
High-density lipoprotein (mmol/L), n = 264	1.2 ± 0.3	1.2 ± 0.3	1.1 ± 0.3	t = 1.761	0.0794
Low-density lipoprotein (mmol/L), n = 264	2.8 ± 0.9	2.82 ± 0.90	2.8 ± 0.9	t = 0.1163	0.9075
Treatment follow-up period (months), n = 465	28.3 ± 17.5	39.8 ± 16.9	22.9 ± 15.0	t = 10.52	< 0.0001
aAPRI score, n = 396	0.42 (0.28-0.81)	0.41 (0.27-0.90)	0.43 (0.29-0.81)	Z = -0.571	0.568
Low (< 0.5)	226 (57.07)	68 (58.62)	158 (56.43)	t = 0.161	0.688
Intermediate (0.5-1.5)	128 (32.32)	36 (31.03)	92 (32.86)	t = 0.125	0.724
High (> 1.5)	42 (10.61)	12 (10.35)	30 (10.71)	t = 0.012	0.913
bFibrosis-4 score, n = 395	0.93 (0.52-1.82)	1.00 (0.50-1.94)	0.89 (0.54-1.74)	Z = -0.232	0.816
Low (< 1.45)	266 (67.34)	74 (63.79)	192 (68.82)	t = 0.940	0.332
Intermediate (1.45-3.25)	82 (20.76)	22 (18.97)	60 (21.50)	t = 0.321	0.571
High (> 3.25)	47 (11.90)	20 (17.24)	27 (9.68)	t = 4.472	0.034

^aAspartate aminotransferase to platelet ratio index score = [(aspartate aminotransferase (U/L)/upper limit of normal)/platelet (10⁹/L)] × 100

^bFibrosis-4 score = [Age (years) × aspartate aminotransferase (U/L)]/[platelet (10⁹/L) × square root alanine aminotransferase (U/L)]

APRI: Aspartate aminotransferase-to-platelet ratio index; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; NAFLD: Nonalcoholic fatty liver disease.